Larazotide for Leaky Gut & Celiac Disease: The Real Clinical Evidence

Larazotide acetate (AT-1001) holds a distinction that no other "leaky gut" or peptide compound can claim: it is the most extensively studied intestinal permeability agent ever tested in human clinical trials. A genuine pharmaceutical candidate derived from a Vibrio cholerae protein, it completed multiple randomized controlled trials in celiac disease, produced a statistically significant Phase 2b result, and entered a Phase 3 program. Yet despite that clinical depth, it is not FDA-approved, its Phase 3 trial was terminated by the sponsor, and no prescription larazotide product exists. This article maps the real clinical evidence — what the RCTs showed, what the Phase 3 outcome means, and how this genuine drug candidate differs from the gray-market peptides marketed for "leaky gut." For context on those gray-market compounds, see our companion article on BPC-157 and leaky gut; for the broader peptide landscape, see our peptides hub.

What is larazotide acetate (AT-1001)?

Larazotide acetate — originally called AT-1001 — is a synthetic eight-amino-acid peptide derived from a protein produced by Vibrio cholerae, the bacterium responsible for cholera. That origin is not incidental: cholera causes massive intestinal permeability increases as part of its pathology, and researchers studying how the bacterium disrupts the gut barrier discovered that one of its proteins also carries a domain capable of blocking that disruption. AT-1001 is a modified fragment of that protein, engineered to function as a tight-junction regulator rather than a toxin^[6].

Its mechanism is specific: larazotide acts as a zonulin antagonist. Zonulin is a signaling protein — described by Alessio Fasano's group as "the only known physiological modulator of intercellular tight junctions"^[2] — that regulates intestinal permeability by loosening the protein complexes (tight junctions) that seal the gaps between enterocytes. In celiac disease, gluten-derived peptides (particularly gliadin) trigger excessive zonulin release, which opens tight junctions, allowing immunogenic gliadin fragments to cross the epithelial barrier and initiate the immune response that drives villous atrophy and symptoms. Larazotide works upstream of this cascade by blocking the zonulin receptor, preventing gliadin from widening the tight junctions in the first place^[5][6].

This mechanism is distinct from dietary restriction (a gluten-free diet addresses gluten exposure) and from immunosuppression (the standard second-line approach in refractory cases). Larazotide was developed as a non-dietary adjunct — a drug that would allow patients on a gluten-free diet to have additional permeability protection against inadvertent gluten exposure, the unavoidable gaps that make strict dietary adherence so difficult in practice.

The celiac disease clinical program: from first-in-human to Phase 3

Larazotide's clinical development represents the most sustained investment in intestinal permeability pharmacology ever undertaken. The program began with Paterson et al.'s 2007 first-in-human proof-of-concept study in Alimentary Pharmacology & Therapeutics^[1]. That single-dose study enrolled celiac disease subjects and demonstrated that AT-1001 was safe and tolerable, with pharmacokinetic and pharmacodynamic profiles supporting the mechanistic hypothesis: subjects receiving AT-1001 showed measurable reduction in intestinal permeability markers compared to placebo, providing the first human evidence that zonulin antagonism could modulate tight junctions in living celiac patients.

A series of Phase 2 trials followed. The Kelly et al. 2013 study in Alimentary Pharmacology & Therapeutics enrolled patients with celiac disease undergoing a gluten challenge — a controlled re-exposure to gluten after a period on a gluten-free diet — and randomized them to larazotide or placebo^[3]. Larazotide reduced gastrointestinal symptoms compared to placebo across multiple doses, reinforcing that the barrier-protective mechanism translated into meaningful symptom attenuation when patients were exposed to the trigger they were trying to avoid.

The pivotal Phase 2b result came in 2015. Leffler et al. published a multi-site randomized controlled trial in Gastroenterology testing three doses of larazotide (0.5 mg, 1 mg, and 2 mg per day) versus placebo in patients with persistent symptoms despite adherence to a gluten-free diet^[4]. The 0.5 mg arm met the study's primary endpoint — a patient-reported outcome measure of abdominal symptoms (the CeD PRO Abdominal Domain score) — with statistical significance (P = 0.022). The 1 mg and 2 mg doses did not separate from placebo on the primary endpoint, an unexpected dose-response pattern that complicated interpretation but did not negate the positive 0.5 mg signal. A subsequent meta-analysis of all larazotide RCTs through 2022 by Hoilat et al. concluded that larazotide was well-tolerated and "seems somewhat superior to placebo in alleviating gastrointestinal symptoms among CD patients undergoing gluten challenge," while noting the signal was less consistent in strictly adherent patients who were not actively challenged with gluten^[7].

The Phase 3 trial: what happened

On the strength of the Phase 2b result, a Phase 3 randomized controlled trial (NCT03569007) was initiated in May 2019. The trial enrolled adult celiac disease patients on a gluten-free diet with persistent symptoms and randomized them to larazotide or placebo, with the primary endpoint being the proportion of subjects classified as binary responders on the CeD PRO Abdominal Domain — a more rigorous threshold than the continuous score improvement used in Phase 2b. The trial reached its primary completion date of July 2022, but was terminated by the sponsor before regulatory submission. No peer-reviewed publication of Phase 3 results has appeared in the medical literature as of mid-2026. Larazotide has not received FDA approval for any indication.

The Phase 3 termination does not erase the Phase 2b positive result — that finding stands in the peer-reviewed literature^[4] and is confirmed in the 2022 meta-analysis^[7]. What it means is that the evidence was not sufficient or consistent enough to support a regulatory submission: a Phase 2b positive result with a complex dose-response, followed by a Phase 3 that did not yield a publishable success. The development of larazotide appears to have stalled at the point where many promising gastrointestinal candidates stall — a real but modest clinical signal that cannot be replicated at the precision required for regulatory approval.

How larazotide differs from gray-market "leaky gut" peptides

The contrast between larazotide and the peptides sold online as "leaky gut cures" is stark — and matters for anyone trying to evaluate the evidence they encounter. Larazotide's entire clinical program was conducted under regulatory oversight: IND applications filed with the FDA, IRB approval at every site, GMP-manufactured study drug, pre-specified endpoints registered in ClinicalTrials.gov before enrollment began, independent data safety monitoring, and results subjected to peer review. Even when the Phase 2b result was unexpectedly dose-dependent, the researchers published that complexity faithfully rather than selectively reporting only the winning arm^[4].

Compare that to BPC-157, perhaps the most widely marketed "leaky gut peptide" sold online. As we document in detail in our BPC-157 evidence review, its entire gut-health evidence base consists of animal experiments — no human randomized controlled trial for any gastrointestinal indication has ever been completed. The peptides are obtained from gray-market suppliers whose products carry no verification of identity, purity, dose, or sterility. The claim that BPC-157 "heals leaky gut" is derived by analogy from rodent intestinal-permeability experiments, not from any controlled human measurement.

Larazotide's Phase 3 termination is genuinely disappointing from a celiac disease treatment perspective, but it reflects the rigor of the evidence standard being applied — a standard that gray-market peptide compounds are never subjected to. The honest conclusion for larazotide is "tested extensively, showed modest Phase 2 benefit, did not meet Phase 3 requirements." The honest conclusion for gray-market "leaky gut peptides" is "untested in humans."

Where larazotide stands now — and what it means for celiac disease treatment

As of mid-2026, no non-dietary pharmacological treatment for celiac disease has received FDA approval. The gluten-free diet remains the only established management strategy. Larazotide's Phase 3 termination reinforces that treating persistent celiac symptoms pharmacologically is harder than the Phase 2b result suggested — the gut's inflammatory and permeability responses to gluten are complex, and blocking a single upstream signal (zonulin-mediated tight junction opening) may not be sufficient to produce consistent, large enough symptomatic benefit across a heterogeneous Phase 3 population.

Other approaches remain in earlier-stage investigation — including prolyl endopeptidases (enzymes that break down gluten before absorption), transglutaminase 2 inhibitors, and immunomodulatory agents — but none have reached the Phase 3 milestone that larazotide did. In that narrow sense, larazotide remains the most clinically advanced intestinal permeability intervention ever tested, even in termination. The pharmacology underlying zonulin antagonism and tight-junction regulation^[2][5] continues to be explored in other conditions, including autoimmune disease and cardiovascular research, though those applications are substantially earlier in development.